for Health Care Providers
Peginterferon alfa plus ribavirin represent the best current treatment available. Yet these therapies have significant toxicities and they are effective in only 50% of those treated. Thus, safe and effective therapies need to be developed for those patients who are currently inadequately served. Through continued HCV research, treatment response should improve, adverse effects should be reduced, and populations for whom treatment are appropriate should expand. As these advances occur, new recommendations will be made.
VA National Hepatitis C Program of the Public Health Strategic Health Care Group: Jane Burgess, ACRN, MS (acting director), Lawrence R. Deyton, MSPH, MD (chief), Michael Rigsby, MD; VA Hepatitis C Resource Centers: Teresa L. Wright, MD, Jason Dominitz, MD, MHS, Samuel B. Ho, MD, Guadalupe Garcia-Tsao, MD; VA Pharmacy Benefits Management: Kathy Tortorice, Pharm.D.; Seattle Working Group: Elizabeth Morrison, MD, George Ioannou, MD; Technical Advisory Group: Timothy R. Morgan, MD, Robert Dufour, MD, Edmund Bini, MD; Core Working Group for the VA HCV Treatment Recommendations: Helen S. Yee, Pharm.D., Sue L. Currie, MS, Jama M. Darling, MD, and Teresa L. Wright, MD.
Conflict of Interest
The authors have no relevant financial interests in this manuscript. Helen S. Yee, Pharm.D. is employed by the Department of Veterans Affairs Medical Center, San Francisco and is affiliated with the University of California, San Francisco. Sue L. Currie, M.A., is employed by the University of California, San Francisco and is affiliated with Department of Veterans Affairs Medical Center, San Francisco. Jama M. Darling, M.D., was employed by the Department of Veterans Affairs Medical Center, San Francisco at the time these guidelines were written and is currently employed by the University of North Carolina at Chapel Hill. Teresa L. Wright, M.D., was employed by the Department of Veterans Affairs Medical Center, San Francisco at the time these guidelines were written and is currently employed by Roche Diagnostics.